Chikungunya vaccine
| Vaccine description | |
|---|---|
| Target | Chikungunya virus |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Ixchiq, others |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. As of 2025, two vaccines have been licensed in some countries. These are Ixchiq, a live attenuated vaccine from Valneva, and Vimkunya manufactured by Bavarian Nordic which utilises virus-like particle technology.
The most commonly reported side effects of Ixchiq include tenderness at the injection site, as well as headache, fatigue, muscle pain, joint pain, fever, and nausea. However the license for Ixchiq has been suspended or restricted in some countries due to the risk of severe side effects, particularly in older people.